Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | June 04, 2026 | June 08, 2026 |
| Latigo Biotherapeutics, Inc.LTGO · Entity 4709 | Director · President and CEO | August 06, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,767 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Sale · Disposed 2,625 · Balance 9,767 F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Latigo Biotherapeutics, Inc.
Report date August 06, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Farzan 2026 Descendants' Trust f/b/o ZAF | 114,453 |
Reported balance
Holding disclosure · report date 2026-08-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 114,453 F1: The Reporting Person is trustee of Farzan 2026 Descendants' Trust f/b/o ZAF |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.19 · Expires 2034-07-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: One-fourth of the total shares subject to this option shall vest one year after July 15, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-02-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.53 · Expires 2035-04-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F3: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is trustee of Farzan 2026 Descendants' Trust f/b/o ZAF
F2: One-fourth of the total shares subject to this option shall vest one year after July 15, 2024, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3: One-fourth of the total shares subject to this option shall vest one year after January 28, 2025, and thereafter 1/48th of the total shares subject to this option shall vest on each monthly anniversary thereof. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 1
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 2,186 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2030-03-23 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 1,281,642 · Balance 0 F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2030-08-18 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 437,413 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.38 · Expires 2031-02-12 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-03 · Disposition to issuer · Disposed 275,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.03 · Expires 2032-02-11 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-04-03 · Disposition to issuer · Disposed 400,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2033-02-10 | Direct | 0 |
Reported balance
After 2024-04-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-04-03 · Disposition to issuer · Disposed 750,000 · Balance 0 F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
F2: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.
F3: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,625 | $10.73 | $28,166.25 |
DisclosureSEC source: 0001808296-26-000004 · form4-06082026_080648.xml · nonDerivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,767 F1 · kind: The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 7,433 | $0.00 Strike: $10.50 | $0.00 |
DisclosureSEC source: 0001808296-26-000002 · form4-06052026_040603.xml · derivative · entry 2 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,433 Underlying: Common Stock · 7,433 shares Expires 2036-06-02 F2 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 7,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001808296-26-000002 · form4-06052026_040603.xml · nonDerivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,392 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001415889-25-015973 · form4-06062025_040604.xml · derivative · entry 2 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2035-06-03 F2 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015973 · form4-06062025_040604.xml · nonDerivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $46.31 | $0.00 |
DisclosureSEC source: 0001415889-24-015150 · form4-06032024_040602.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 750,000 | Not disclosed Strike: $6.78 | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · derivative · entry 6 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires 2033-02-10 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 400,000 | Not disclosed Strike: $10.03 | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · derivative · entry 5 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400,000 shares Expires 2032-02-11 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 275,000 | Not disclosed Strike: $35.38 | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · derivative · entry 4 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 275,000 shares Expires 2031-02-12 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 437,413 | Not disclosed Strike: $5.63 | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · derivative · entry 3 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 437,413 shares Expires 2030-08-18 F3 · price: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. F3 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerStock Option (right to buy) · Derivative | 1,281,642 | Not disclosed Strike: $2.57 | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · derivative · entry 2 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,281,642 shares Expires 2030-03-23 F2 · price: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. F2 · derivative.exercise_date: This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:55 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | Disposition to issuerCommon Stock | 2,186 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010433 · form4-04052024_040430.xml · nonDerivative · entry 1 Farzan Nima · CIK 0001808296 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:38 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $48.79 | $0.00 |
DisclosureSEC source: 0001209191-23-035441 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001209191-23-009204 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 750,000 shares Expires 2033-02-10 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 16:01 UTC Amendment | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $6.78 | $0.00 |
DisclosureSEC source: 0001209191-23-009620 · doc4a.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2033-02-10 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2023 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2027, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:24 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Options (right to buy) · Derivative | 8,293 | $0.00 Strike: $32.95 | $0.00 |
DisclosureSEC source: 0001209191-22-034042 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,293 Underlying: Common Stock · 8,293 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:00 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee Stock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $10.03 | $0.00 |
DisclosureSEC source: 0001209191-22-009740 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-02-11 F1 · derivative.exercise_date: One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 8,293 | $0.00 Strike: $51.48 | $0.00 |
DisclosureSEC source: 0001209191-21-037790 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,293 Underlying: Common Stock · 8,293 shares Expires 2031-05-31 F1 · derivative.exercise_date: The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 12, 2021 Filed Feb 16, 2021 22:54 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantEmployee stock option (right to buy) · Derivative | 275,000 | $0.00 Strike: $35.38 | $0.00 |
DisclosureSEC source: 0001209191-21-010892 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-02-12 F1 · derivative.exercise_date: The Option vests and becomes exercisable over time at the following rate: 1/48th of the total number of shares subject to the Option shall vest each month in equal installments starting on March 1, 2021. Read SEC document |
| May 29, 2020 Filed May 29, 2020 21:19 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $28.74 | $0.00 |
DisclosureSEC source: 0001209191-20-032991 · doc4.xml · derivative · entry 1 Farzan Nima · CIK 0001808296 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2030-05-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on each of June 2, 2020, September 2, 2020, December 2, 2020 and March 2, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.